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Empagliflozin (EMPA), a drug approved for type 2 diabetes management, reduced
cardiovascular death but is unknown if it reduces myocardial infarction. We sought
to investigate: (i) the effect of EMPA on myocardial function and infarct size after
ischemia/reperfusion in mice fed with western diet (WD), (ii) the underlying signaling
pathways, (iii) its effects on cell survival in rat embryonic-heart-derived cardiomyoblasts
(H9C2) and endothelial cells (ECs). To facilitate the aforementioned aims, mice were
initially randomized in Control and EMPA groups and were subjected to 30min ischemia
and 2 h reperfusion. EMPA reduced body weight, blood glucose levels, and mean arterial
pressure. Cholesterol, triglyceride, and AGEs remained unchanged. Left ventricular
fractional shortening was improved (43.97 ± 0.92 vs. 40.75 ± 0.61%) and infarct size
reduced (33.2 ± 0.01 vs. 17.6 ± 0.02%). In a second series of experiments, mice were
subjected to the above interventions up to the 10th min of reperfusion and myocardial
biopsies were obtained for assessment of the signaling cascade. STAT3 was increased
in parallel with reduced levels of malondialdehyde (MDA) and reduced expression of
myocardial iNOS and interleukin-6. Cell viability and ATP content were increased in
H9C2 and in ECs. While, STAT3 phosphorylation is known to bestow infarct sparing
properties through interaction with mitochondria, we observed that EMPA did not directly
alter the mitochondrial calcium retention capacity (CRC); therefore, its effect in reducing
myocardial infarction is STAT3 dependent. In conclusion, EMPA improves myocardial
function and reduces infarct size as well as improves redox regulation by decreasing
iNOS expression and subsequently lipid peroxidation as shown by its surrogate marker
MDA. The mechanisms of action implicate the activation of STAT3 anti-oxidant and
anti-inflammatory properties.
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INTRODUCTION
In the EMPA-REG OUTCOME trial, empagliflozin (EMPA),
a selective inhibitor of the sodium glucose co-transporter
2 (SGLT2), reduced the risk of the combined endpoint of
hospitalization for heart failure or cardiovascular death, in type
2 diabetic patients (T2D) (Fitchett et al., 2016). The mechanism
by which EMPA induces cardiovascular benefits is obscure.
However, the discrepancy in the Hazards ratios (HRs) for non-
fatal myocardial infarctions (HR 0.87 [95% CI 0.70, 1.09]) and
non-fatal strokes (HR 1.24 [0.92, 1.67]) indicates that benefits
of EMPA may do not involve classical effects on atherosclerosis
(Vettor et al., 2017). Although the results of the EMPA-REG trial
were impressive, the cardioprotectivemechanisms of the drug are
still speculative. There is no in vitro, or in vivo study investigating
if EMPA exerts its cardioprotection through the reduction of
myocardial infarction after ischemia/reperfusion (I/R) injury.
In the present study we investigated the effect of EMPA on
myocardial function and infarction after I/R, in a mouse model
with diet-induced T2D. In order to achieve this goal we recruited
a murine model of diet induced metabolic syndrome, known to
manifest T2D. The C57BL/6 mouse strain has been indicated
to be prone in T2D and atherosclerosis following a high-fat,
WD for prolonged time (Surwit et al., 1988; Phillips et al.,
2003). We selected a dose of 10 mg/kg/day of EMPA which has
been calculated based on the inter-species pharmacokinetic and
metabolic parameters between rodents and humans (e.g., half-
life ∼1–2 h in rodent and 10–12 h in man). This dose has been
previously shown to correspond to the equivalent active dose in
humans (Cheng et al., 2016). Additionally, since we know that
SGLT2 is highly specifically expressed in the kidney and very
minimally in the heart (Chen et al., 2017) we sought to investigate
the mechanism by which EMPA may exert cardioprotective
effects based on intracellular signaling cascades independent of
SGLT2, as it has been shown that EMPA exerts pleiotropic effects
in aorta and in adipose tissue (Steven et al., 2017).
To further investigate a direct cardioprotective effect of
EMPA, we evaluated its effect on an in-vitro model of injury: we
exposed rat embryonic-heart-derived cardiomyoblasts (H9C2)
and endothelial cells (ECs) to hypoxia/reoxygenation. Moreover,
taking under consideration that mitochondria and redox aspects
play very important role in cardioprotection (Penna et al., 2013;
Pagliaro and Penna, 2015) we also focused on redox signaling and
mitochondrial susceptibility to transition.
MATERIALS AND METHODS
For Complete Methods please see Supplementary Material.
In Vivo Experiments
Animals
A total of thirty five male 8-week old C57BL/6J animals
were treated according to the Directive 2010/63/UE European
Convention for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes, and conformed to
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No.
85-23, revised 1985). The experimental protocol used in this
study was approved by Ethical Committee of University of
Athens and the Veterinary Authorities of Region of Athens
Greece (License Number: 1758/24/3/2017).
Experimental Protocol
Mice were fed a Western diet (WD) (TD 88137, Harlan-Teklad;
containing 21% fat by weight, 0.15% by weight cholesterol, and
19.5% by weight casein without sodium cholate), for 14 weeks
(Surwit et al., 1988; Phillips et al., 2003). At the 8th week of
feedingmice were randomized into two groups: (i) Control group
(n = 15) in which DMSO 5% in Water For Injection (WFI)
solution was given through gavage for additional 6 weeks and
(ii) EMPA group (n= 15), in which EMPA was administered (10
mg/kg/day) in 5% DMSO/WFI through gavage for additional 6
weeks.
The EMPA dose was selected according to previous reports
(Oelze et al., 2014; Habibi et al., 2017). At the end of treatment
eighteen mice (n = 9 per group) subjected to 30min myocardial
ischemia followed by 2h reperfusion to determine the infarct
size. Twelve mice (n = 6 per group) were subjected to the
above interventions up to the 10th min of reperfusion, to obtain
myocardial biopsies from the ischemic area for Western Blot
analysis.
The following parameters were determined at baseline (Day
0), at the end of 8th week and at the end of the 14th week (end
of treatment): body weight (BW), glucose levels. The following
parameters were determined at baseline (Day 0), and at the end
of the 14th week (end of treatment): cholesterol and triglycerides,
arterial pressure, and myocardial function by echocardiography.
Malondialdehyde (MDA) as a marker of lipid peroxidation was
determined at the end of 8th week and at the end of 14th week,
while advanced glycation end products (AGE) were determined
at the end of 14th week.
Murine Model of Ischemia-Reperfusion Injury
Anesthesia/surgical preparation
General anesthesia was induced via intraperitoneal injection of
a mixture containing ketamine, xylazine, and atropine (100, 20,
and 0.6 mg/kg respectively). A cuffed tracheal tube was placed
via a tracheotomy (ventral midline incision) for mechanical
ventilation of the lungs with a 95%O2 via a volume-cycled animal
ventilator (150 strokes/min, tidal volume 200 µl). Consequently,
the animals were placed in left-lateral recumbence and the chest
was surgically opened with a left thoracotomy. The chest was
opened through the left fourth intercostal space. The beating
heart was exposed and the pericardium was incised. The left
anterior descending coronary artery was ligated with a 6-0 silk
suture. The occlusion of coronary artery in this region leads
to ischemia of a large area of the anterolateral and apical left
ventricular wall. Ischemia was induced by tightening of the suture
against a small piece of polyethylene tubing. Ischemia resulted
in a change in the color (i.e., cyanotic) of the myocardium and
was maintained for 30min. At the end of the ischemic period,
the suture was released in order to induce reperfusion of the
myocardium for up to 2 h. In order to determine/quantify the
degree of irreversible myocardial injury (i.e., infarction) resulting
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from the ischemia and reperfusion insult with and without
indicated treatment, infarct areas were evaluated. For this reason,
myocardium was excised and aorta was catheterized. After the
tightening of the suture, Evan’s Blue solution (2.5% in Water
for Injection-WFI) was infused through the catheter for the
identification of the normally perfused part of the myocardium.
Afterwards, hearts were frozen for 24 h and then sliced in 1–
2mm sections, which were incubated for 20min in Triphenyl-
Tetrazolium Chloride Solution (TTC, 1% in PBS pH = 7.4) for
the identification of the area-at-risk and the infarct area (Bibli
et al., 2015).
Histopathology/Histomorphometery
For each heart, the overall size of the myocardial slice (All/A), the
area-at-risk (Risk/R) and the infarct (Infarct/I) were determined.
R was expressed as a percentage of the A area (R/A %), and I was
expressed as a percentage of the R (I/R %) (Bibli et al., 2015).
Blood Biochemistry
Mice were fasted overnight prior to blood sampling. Blood was
collected from the tail vein by puncturing the vessel vertically
with a 23-gauge needle at baseline, at the 8th week and at the
end of the treatment periods. Blood glucose levels were measured
by using a hand-held glucometer (Onetouch Verio IQ Lifescan,
Johnson & Johnson Company).
For the assessment of lipid levels and MDA measurement,
blood samples were collected at the beginning of the treatment
period and at the end of the study. Blood was centrifuged and
plasma was stored at −80◦C. Plasma cholesterol and triglyceride
concentrations were measured spectrophotometrically using
commercial kits (DiaSys Diagnostic Systems GmbH, Cholesterol
FS 10130021, and Triglycerides FS 10571 021). The MDA
concentration was determined spectrophotometrically at 586 nm
and expressed as µM (Oxford Biomedical Research Colorimetric
Assay for lipid peroxidation) as we have previously described
(Andreadou et al., 2004).
Arterial Pressure (AP) Monitoring
At baseline and at the end of treatment, non-invasive arterial
pressure was measured on awake mice using CODA Monitor
tail-cuff system (Kent Scientific Co, Torrington, CT USA). The
mice were placed for 10min inside a heated chamber (34◦C) and
then positioned in a restrainer over a heating pad. They were
allowed a 5min acclimation period following cuff positioning
and 20 consecutive AP determination cycles we conducted.
All measurements were recorded on the CODA software and
presented in Table 1. In case signs of discomfort were present,
the animal was returned to the heated chamber and re-examined
1 h later.
Echocardiography
At baseline and at the end of the treatment, M-mode
echocardiography was performed as previously described
(Papathanasiou et al., 2015) to measure left ventricular (LV)
end-diastolic diameter (EDD), LV end-systolic diameter (ESD),
and LV posterior wall thickness at diastole (PWT) and to
calculate the ratio of LV radius to PWT (r/h) and the percentage
of LV fractional shortening FS (%).
TABLE 1 | Cholesterol and triglyceride levels, mean arterial pressure values and
echocardiography data at baseline and after 14 weeks of treatment in Control (n =
10) and EMPA (n = 10) groups.
Control EMPA
Triglycerides Baseline (mg/dl) 37.91 ± 3.28 54.36 ± 10.12
Triglycerides 14 weeks (mg/dl) 36.93 ± 9.05* 55.41 ± 8.59*
Cholesterol Baseline (mg/dl) 145.5 ± 16 139.2 ± 12
Cholesterol 14 weeks (mg/dl) 233.6 ± 43* 191.9 ± 20.92*
Diastolic AP Baseline (mmHg) 80.51 ± 2.0 79.17 ± 2.2
Diastolic AP 14 weeks (mmHg) 73.18 ± 2.1 70.87 ± 2.1*
Systolic AP Baseline (mmHg) 106.70 ± 2.3 105.35 ± 2.4
Systolic AP 14 weeks (mmHg) 102.55 ± 2.0 96.91 ± 2.2*
Mean Arterial Pressure Baseline (mmHg) 88.9 ± 2.32 87.56 ± 2.4
Mean Arterial Pressure 14 weeks (mmHg) 82.58 ± 2.6 79.22 ± 2.1*
HR Baseline 592.20 ± 5.27 627.90 ± 11.29#
HR 14 weeks 702.37 ± 10.31* 687.20 ± 5.46*
ECHOCARDIOGRAPHY
LVEDD, mm Baseline 2.90 ± 0.07 2.96 ± 0.06
LVEDD, mm 14 weeks 3.20 ± 0.07* 3.04 ± 0.07
LVESD, mm Baseline 1.54 ± 0.05 1.59 ± 0.03
LVESD, mm 14 weeks 1.90 ± 0.05* 1.71 ± 0.06#
PWd, mm Baseline 0.79 ± 0.01 0.77 ± 0.01
PWd, mm 14 weeks 0.74 ± 0.01* 0.76 ± 0.01#
PWs, mm Baseline 1.27 ± 0.01 1.27 ± 0.01
PWs, mm 14 weeks 1.23 ± 0.01* 1.24 ± 0.01*
FS% Baseline 47.07 ± 0.65 46.14 ± 0.31
FS% 14 weeks 40.75 ± 0.61* 43.97 ± 0.92#
r/h Baseline 1.84 ± 0.06 1.91 ± 0.05
r/h 14 weeks 2.15 ± 0.07* 1.98 ± 0.05
*p < 0.05 vs. Baseline, #p < 0.05 vs. Control group. Left ventricular (LV) end-diastolic
(EDD) and end-systolic dimension (ESD); posterior wall thickness (PW) in diastole (d) and
systole (s); percentage fractional shortening (FS%); ratio of LV radius to PWT (r/h).
Western Blot Analysis in Myocardial Tissue
Myocardial tissues were pulverized and the powder was
homogenized in lysis buffer (1% Triton X-100, 20mM Tris pH
7.4–7.6, 150mM NaCl, 50mM NaF, 1mM EDTA, 1mM EGTA,
1mM Glycerolphosphatase, 1% SDS, 100mM PMSF, and 0.1%
protease phosphatase inhibitor cocktail). After centrifugation at
11,000 g for 15min at 4◦C, supernatants were collected and
protein content was assessed using the Lowry method. The
supernatant was mixed with Dave’s buffer (4% SDS, 10% 2-
mercaptoethanol, 20% glycerol, 0.004% bromophenyl blue, and
0.125M Tris·HCl). The samples were boiled at 100◦C for 10min
and stored at −80◦C. An equal amount of protein was loaded
in each well and then separated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis 7.5–11% and transferred onto
a polyvinylidene difluoride membrane (PVDF). After blocking
with 5% non-fat dry milk, membranes were incubated overnight
at 4◦C with the following primary antibodies:
p-eNOS (Ser1177), eNOS, p-Akt (Ser473), Akt, p-ERK 1/2
(Thr202/Tyr204), p-GSK3β (Ser9), t-GSK3β, pAMPKα(Ser172),
tAMPKα, p-STAT3 (Tyr705), t-STAT3, iNOS, p-NF-κB (p65)
(Ser536), t- NF-κB (p65), GAPDH, β-tubulin, β-actin (Cell
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Signaling Technology, Beverly, MA, USA) and IL-6 (Santa-
Cruz Biotechnology Inc., USA). PVDF membranes were then
incubated with secondary antibodies for 2 h at room temperature
(goat anti-mouse and goat anti-rabbit HRP; Cell Signaling
Technology, Beverly, MA, USA) and developed using the GE
Healthcare ECL Western Blotting Detection Reagents (Thermo
Scientific Technologies, Bioanalytica, Athens, Greece). Relative
densitometry was determined using a computerized software
package (NIH, USA), and relative ratios were used for statistical
analysis (Bibli et al., 2015, 2016).
Advanced Glycation End-Products (AGE)
Fluorescence Measurement
The fluorescence intensity of plasma samples was measured
at 440 nm after excitation at 370 nm, using a fluorescence
spectrophotometer (Infinite R© 200 PRO NanoQuant Plate
Reader) operating at room temperature. Emission and excitation
slit widths were set at 5 nm. Fluorescence was expressed as the
Intergrated Fluorescence intensity in arbitrary units (AU), as
previously described (Yanagisawa et al., 1998).
In Vitro Experiments
Effects on Cellular Level
Cell culture and in vitro hypoxia/reoxygenation assay
Endothelial cells (ECs) were purchased from Lonza (Basel,
Switzerland) and cultured as described by the manufacturer’s
instructions. The embryonic rat heart-derived cell line H9C2
was obtained fromAmerican Type Culture Collection (Manassas,
VA, USA). Cells were maintained in DMEM high glucose (HG)
with 10% FBS, 4mM glutamine and grown to subconfluence
prior to experiments. In parallel experiments H9C2 cells were
cultured for 24 h either alone or in combination with 1 mg/ml
AGE and untreated or treated with EMPA (100 or 500 nM)
(Panchapakesan et al., 2013). ECs, maintained for 24 h in 5%
FBS, were cultured either alone or in combination with AGE
and untreated or treated with EMPA (100 or 500 nM). At day 2,
cells were subjected to in vitro hypoxia for 24 h (5% CO2/95%
N2 humidified atmosphere, yielding 1% O2 concentrations) and
subsequently reoxygenated for 3 h (75% N2, 20% O2, and 5%
CO2).
ATP content assay
To determine the level of cellular ATP content as an
indirect measurement of viable cells, ATP content was
performed using ATP assay kit according to manufacturer’s
instructions (Sigma Aldrich). Briefly, ECs and H9C2, treated
as indicated, were subjected to in vitro ischemia for 24 h.
After reoxygenation, ATP was quantitatively determined by
measuring luminescence generated in an ATP-dependent
luciferin-luciferase bioluminescence assay. A standard curve was
used in each experiment, and the samples were diluted to be
in the linear range of the standard curve. All experiments were
performed in triplicate.
Cell viability assay
Cell viability was assessed by MTT as described previously
(Baldanzi et al., 2002). Cells were seeded on 96-well plates at 5 ×
103 cells/well. ECs and H9C2 which had either been treated with
the indicated stimuli or had been left untreated were subjected
to in vitro ischemia and reoxygenation. After treatments, cells
were incubated with 1 mg/ml MTT for 2 h. Subsequently, the
medium was removed and 100 µl of dimethylsulfoxide (DMSO)
was added to each well. After 1 h, the 96-well plate was read
by an enzyme-linked immunosorbent assay (ELISA) reader at
570 nm for absorbance density values to determine cell viability.
All experiments were performed in triplicate.
Western blot analysis in cells
Cells were lysed (50mM Tris HCl [pH 8.3], 1% Triton X-100,
10mM PMSF, 100 U/mL aprotinin, 10 µM/mL leupeptin) and
protein concentrations were obtained as previously described
(Togliatto et al., 2011). Proteins (50 µg) were subjected to SDS-
PAGE, transferred into nitrocellulosemembrane, blotted with the
indicated antibodies (anti-RAGE antibody cat. No. sc-8230, and
anti-b-actin antibody cat. No. sc-47778, purchased from Santa
Cruz, Biotechnology, Germany) and processed as previously
described (Togliatto et al., 2011). Densitometric analysis was used
to calculate the differences in the fold induction of protein level
normalized to β-actin. Values are reported as relative amounts.
Effects on Subcellular Level
Mitochondrial isolation
Five additional C57BL/6mice weighting 25–30 g were euthanized
by cervical dislocation, and their hearts were quickly excised,
rinsed, and cut in the isolation buffer (225mMmannitol, 75mM
sucrose, 10mM HEPES-Tris, 1mM EGTA-Tris, pH 7.4). Then,
the tissue was homogenized in the isolation buffer supplemented
with 0.1 mg/ml Nagarse by using a glass-Teflon homogenizer.
The homogenate was diluted in isolation buffer supplemented
with 0.2% w/v bovine serum albumin, centrifuged at 500 g at
4◦C, and filtered through a 150-mm mesh for the removal of
cellular debris. The supernatant was further centrifuged at 8,000 g
to separate the mitochondrial from the cytosolic fraction. The
pellet, consisting of mitochondria was washed with isolation
buffer without bovine serum albumin and centrifuged at 8,000 g.
The final pellet was used for protein determination and further
assays.
Calcium retention capacity assay
The calcium retention capacity (CRC) assay was performed as
previously described (Chatzianastasiou et al., 2016) in order
to determine the susceptibility of mitochondria to undergo
permeability transition. Isolated mitochondria were diluted
in mitochondrial assay buffer (KCl 137mM, KH2PO4 2mM,
HEPES 20mM, EGTA 20mM, glutamate/malate 5mM, pH
7.2) at a concentration of 0.25 mg/ml. Extramitochondrial
Ca2+ was measured by Calcium Green-5N (1mM) fluorescence
using a Fluoroskan Ascent FL plate reader (Thermo Electron,
Waltham, MA). Each minute, pulses of 10mM Ca2+ were
added to each well, up to a point when the accumulated
Ca2+ was released due to mitochondrial transition through the
opening of themitochondrial permeability transition pore (PTP).
Cyclosporine A (CsA) (1 mg/ml), was used as a positive control.
Mitochondria were exposed to different concentrations of EMPA,
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and their CRC was determined: All experiments performed in
five repetitions.
Statistical analysis
All values were denoted as means ± S.E.M. For animal studies
and tissue experiments comparisons of numeric variables among
the groups were analyzed using unpaired two-tailed Student’s t-
test, while those originating by different time points belonging to
the same group were analyzed using paired two-tailed Student’s
t-test. A calculated p < 0.05 was considered to be statistically
significant.
For mitochondria and cell culture experiments, the
D’Agostino–Pearson test was used to test normality. Data
on cell viability assay, ATP content assay and on densitometric
analysis for Western blots were analyzed using 1-way ANOVA,
followed by Tukey’s multiple comparison test. The cut-off for
statistical significance was set at p < 0.05 (∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001). All statistical analyses were carried out using
GraphPad Prism version 5.04 (Graph Pad Software, Inc.).
RESULTS
EMPA Reduces Body Weight, Mean Arterial
Pressure, Glucose, and Lipid Peroxidation
Levels without Altering Lipid Levels and
Age Products
The experimental protocol of the study is illustrated in
Figure 1A. In both groups, BW increased after 14 weeks of WD
feeding. At the end of treatment, EMPA reduced significantly
the BW (Figure 1B) and fast blood glucose levels (250 ± 18
mg/dL vs. 172 ± 8 mg/dL, ∗p < 0.05, Figure 1C) in comparison
to Control. Mean arterial pressure (MAP) was significantly
reduced from baseline after 6 weeks treatment in the EMPA
group (Table 1). Cholesterol and triglyceride levels did not differ
between study groups at the end of treatment; however, they
were significantly elevated compared to baseline values (Table 1).
AGE levels were similar between the study groups at the end of
treatment period (Figure 1D). Reduced levels of the biomarker of
lipid peroxidation, malondialdehyde (MDA) in circulation was
observed in the EMPA group compared to the Control group
(Figure 1E, p < 0.05).
Cardiac Function Is Improved with EMPA
Pretreatment in Mice Treated with WD
Echocardiography revealed a reduction in the myocardial
function after 14 weeks WD feeding as shown by the left
ventricular fractional shortening (LVFS%; 43.97 ± 0.92 vs. 40.75
± 0.61%, p= 0.001), due to deterioration of both LV end-systolic
and end-diastolic dimensions (Table 1). These changes were not
evident after EMPA treatment (Table 1, Figure S2).
EMPA Pretreatment Reduces Myocardial
Infarct Size in Mice Treated with WD
Three animals from the Control group and one animal from
the EMPA group were excluded for different technical and/or
hemodynamic reasons (severe bleeding and infarction detected
outside the area at risk). As a result, 14 animals completed the
study, Control (n= 6) EMPA (n= 8). Myocardial infarct size was
reduced in EMPA group (33.2± 0.01 vs. 17.6± 0.02%, p < 0.05)
(Figure 2A), with no difference in the area at risk (Figure 2B).
EMPA Pretreatment Induces
Cardioprotection through STAT3
Activation, Independently of the
Reperfusion Injury Salvage Kinase (RISK)
Pathway and AMPKα Activation
EMPA pretreatment did not activate Akt (Figure 3A), eNOS
(Figure 3B), did not phosphorylate GSK3β on its inhibitory site
(Figure 3C), did not activate p-44/p-42(ERK 1/2) (Figure 3D),
and had no effect on AMPKα phosphorylation (Figure 3E).
EMPA increased both STAT3 expression and phosphorylation
(Figure 3F, p < 0.05) compared to the untreated group.
Additionally, EMPA did change neither the phosphorylation
nor the expression of nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) (Figure 4A). Pretreatment with
EMPA resulted in reduced levels of myocardial inteleukin-6 (IL-
6) (Figure 4B, p < 0.05) and of inducible nitric oxide synthase
(iNOS) expression (Figure 4C, p < 0.05).
Evaluation of the Effects of EMPA on
Isolated Heart Mitochondria
In order to determine the direct effects of EMPA on
mitochondrial transition, we recruited an in vitro experiment
on isolated murine heart mitochondria. EMPA tested in
concentrations of 50µM−50 nM had no effect on mitochondrial
CRC. Cyclosporine was used as a positive control and increased
mitochondrial CRC at a dose of 1µg/ml (Figures 5A,B; ∗∗∗p <
0.001 vs. all other study groups).
EMPA Protects H9C2 and EC Cells against
Hypoxia/Reoxygenation Injury in a Diabetic
Milieu
In order investigate a direct cardioprotective effect of EMPA
we exposed H9C2 and ECs to hypoxia/reoxygenation. EMPA
at 500 nM increased H9C2 cell viability and ATP content
(Figures 6A,C). More importantly, it was able to protect cells
even when AGE was used to mimic the diabetic milieu. Similar
results were obtained in ECs (Figures 6B,D). Consistent with
AGE expression in vivo, no changes in receptor for advanced
glycation endproducts (RAGE) expression was detected in vitro
(Figure 6E).
DISCUSSION
EMPA treatment in a Type 2 Diabetes animal model, reduced
myocardial infarct size, preserved myocardial function after I/R
injury, increased cell viability and ATP content in H9C2 and
in ECs even when AGE was used to mimic the diabetic milieu.
The present study also highlights that EMPA increased STAT3
phosphorylation and expression and reduced myocardial IL-6
and iNOS expressions regulating inflammatory responses and
redox signaling in the ischemic myocardium.
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FIGURE 1 | Empagliflozin reduces body weight, glucose levels, and lipid peroxidation levels without altering AGE products. (A) Experimental work flow. (B) Effects of
diet manipulation and empagliflozin treatment on mice BW (*p < 0.05 vs. Baseline, #p < 0.05 vs. Control). (C) Effects of diet manipulation and empagliflozin
treatment on fasting glucose levels (*p < 0.05 vs. Baseline, #p < 0.05 vs. Control). (D) AGE (AU) measured as Intergrated Fluorescence at emission 370 nm and (E)
effects of diet manipulation and empagliflozin treatment on circulating MDA (uM) levels (*p < 0.05 vs. Control).
Diabetes mellitus increases myocardial susceptibility to I/R
injury (Miki et al., 2012). Glycotoxicity plays a major role
in this defect by increasing formation of AGE products
and the RAGE-induced signaling cascade, leading to vascular
dysfunction. RAGE blockade has been demonstrated to be
a potential therapeutic approach for treatment of I/R-injury
(Park et al., 2015). SGLT2 inhibitors are highly efficient in
preventing glucotoxicity, by reducing formation of AGE and
induction of RAGE as it is shown in experimental studies
(Oelze et al., 2014). In our in vivo model EMPA did not alter
AGE; additionally, did not alter RAGE expression in H9C2
cells. These findings are consistent with data showing that
EMPA, independently of AGE accumulation, exerts pleiotropic
protective effects on myocardial function and structure in
diabetic db/db mouse (Habibi et al., 2017). In compliance with
our findings the administration of EMPA at a similar dose
used in our study improved aortic remodeling independently
of AGE and RAGE formation in aortic tissue declaring
that EMPA activity can be AGE-independent (Oelze et al.,
2014).
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FIGURE 2 | Empagliflozin pretreatment reduces myocardial infarct size in mice
treated with WD. (A) Representative Graphs of Infarct/Risk Area (I/R) %.
Individual animals represented as a scatter plot with dots in the Control group
and squares in the EMPA group. Results plotted as Mean ± SEM (*p < 0.05
vs. Control). (B) Risk/All Area (R/A) %.
Reperfusion Injury Salvage Kinase (RISK) and Survivor
Activating Factor Enhancement (SAFE) pathways are the main
mediators of cardioprotection leading to reduction of infarct
size (Heusch, 2015). We did not find any differences between
the EMPA and Control groups in the phosphorylation and
expression of Akt, eNOS, ERK1/2, and GSK3β in the ischemic
myocardium, indicating a RISK independent pathway in EMPA-
mediated cardioprotection. This is in agreement with a recent
study demonstrating that EMPA did not phosphorylate Akt or
ERK1/2 in cardiomyocytes (Habibi et al., 2017). AMPK is a kinase
that serves as a key modulator of cellular bioenergetics, and
agents acting on AMPK activation, such as metformin, induce
cardioprotective effects (Calvert et al., 2008). Canagliflozin,
an SGLT2 inhibitor causes a substantial AMPK activation
in vitro. In contrast, EMPA caused only a modest AMPK
activation at high concentrations, indicating that this effect
is unlikely to be relevant in vivo (Hawley et al., 2016). We
confirmed the above findings in vivo showing that EMPA did
not phosphorylate AMPK, specifying that its cardioprotective
effects are independent of AMPK activation. We must mention
that all the above signaling events were tested at the time
point of the 10th min of reperfusion. This time point was
chosen since many of the cardioprotective mechanisms are
activated during the first minutes of reperfusion as previously
shown (Andreadou et al., 2012, 2015; Kleinbongard et al., 2017).
However, components of the RISK pathway such as Akt may be
activated after the 10th min of reperfusion (Kleinbongard et al.,
2017); therefore we should clarify that in our protocol there is
no activation of RISK pathway and AMPK at this specific time
point. In addition to the RISK pathway, SAFE and in particular
STAT3 activation, is one of the main mediators of triggering
cardioprotection (Andreadou et al., 2015; Kleinbongard et al.,
2017). Chronic treatment with the SGLT2 inhibitor, dapagliflozin
in vivo, activated the STAT3 signaling pathway, which on turn
enhancedM2macrophage activation, resulting in the attenuation
of cardiac fibrosis molecularly by myocardial iNOS and IL-6
reduced levels (Lee et al., 2017). This effect was more evident
with the use of the specific SGLT2 inhibitor dapagliflozin
than with the SGLT1/SGLT2 inhibitor phlorizin, implying that
compensatory SGLT1 activation after administration of specific
SGLT2 inhibitors may play a role in ventricular remodeling
(Lee et al., 2017). We found that 6 weeks administration of
EMPA resulted in a significant activation of STAT3 at tyrosine
705. We investigated the phosphorylation on Tyr705, since
Tyr705 is the primary phosphorylation site of STAT3 (Andreadou
et al., 2015). Moreover, the latter study has deduced that STAT3
activation is mediated through decrease of reactive oxygen
species (ROS) accumulation in the myocardium. In compliance
with the abovementioned findings we have found that in EMPA
treated mice circulating levels of MDA are reduced compared
to Control. The decrease in lipid peroxidation biomarker MDA
seems to be a key element in redox regulating effects of
EMPA.
STAT3 phosphorylation has a direct effect on maintaining
mitochondrial integrity and attenuating mitochondrial
permeability transition pore (MPTP) opening (Heusch,
2015), a key process that is pivotal for the cardiomyocyte
survival after ischemia-reperfusion (Bernardi and Di Lisa, 2015;
Hausenloy et al., 2016). Additionally, this pore is important
in the induction of ROS induced ROS release (RIRR) and can
furtherly lead to increased oxidative decay in the cardiomyocytes
(Penna et al., 2013). To elucidate whether EMPA exerts its
cardioprotective effects through inhibition of MPTP directly,
or if the infarct sparing properties are mediated through STAT3
activation, we evaluated the Ca2+ retention capacity of isolated
heart mitochondria after a series of Ca2+ pulses and increasing
EMPA concentrations. Since we observed that EMPA did not
alter the mitochondrial susceptibility to permeability transition,
we concluded that the effect of EMPA in reducing myocardial
infarction is STAT3 dependent. However, we must mention
that we tested the efficacy of EMPA on mitochondrial transition
under normoxic conditions, addressing the direct link between
EMPA’s cardioprotective potential and mitochondrial retention
capacity. Whether the chronic administration of EMPA may
alter mitochondrial susceptibility to transition in vivo, when
subjected to I/R, as well as the underlying induced signaling
cascades is a topic of further investigations. Therefore, our next
step focused on the signaling cascade complementary to STAT3
activation.
Activation of STAT3, leads to its translocation to the nucleus
to function as a transcriptional factor. STAT3 might exhibit a
differential role when translocated to the nucleus as it can bind
to the promoter of iNOS directly, inhibiting its expression and
mitigating cardiomyocyte apoptosis (Su et al., 2016). This is an
important finding, as far as the cardioprotective properties of
EMPA are concerned, knowing that iNOS is a key contributing
molecule in nitrosative stress as well as it possesses deleterious
role in inflammatory processes and that diabetes is per se a
redox-mediated disease. NO derived from iNOS may react with
anion superoxide to form peroxynitrite, which may sustain
lipid peroxidation (Sag et al., 2013). Therefore, the decreased
MDA levels can be directly correlated with the decreased iNOS
expression in the EMPA group.
Furthermore, STAT3 can interfere with key molecules
implicated in inflammation. NF-κB is a key mediator of
inflammatory response, as it leads to the transcription of
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FIGURE 3 | Empagliflozin induces cardioprotection through activation of STAT-3 and independently of RISK pathway and of AMPK activation. Representative western
blots and relative densitometry graphs of (A) p-Akt (S473)/t-Akt and t-Akt/GAPDH (B) p-eNOS(S1177)/t-eNOS and t-eNOS/GAPDH (C) p-GSK-3β(S9)/t-GSK-3β and
t-GSK-3β/GAPDH (D) p-ERK1/2 (Thr202/Tyr204)/t-ERK1/2 and t-ERK1/2/GAPDH (E) p-AMPKα(S172)/t-AMPKα and t-AMPKα/GAPDH (F) p-STAT3(Tyr705)/t-STAT3
and t-STAT3/β-actin (*p < 0.05 vs. Control). p-Akt, t-Akt (A) and p-ERK1/2, t-ERK1/2 (D) proteins were detected on the same gel and share the same image of
GAPDH, serving as loading Control. This was also the case for p-eNOS, t-eNOS (B), p-AMPKα, and t-AMPKα (E).
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FIGURE 4 | Empagliflozin reduces myocardial iNOS and IL-6 expression. Representative western blots and relative densitometry graphs of (A) p-NF-κB (p65) (S536)/
t-NF-κB (p65) and t-NF-κB (p65)/β-tubulin (B) IL-6/ β-tubulin (*p < 0.05 vs. Control) and (C) iNOS/ β-tubulin (*p < 0.05 vs. Control). p-NFκB(p65), t-NFkB(p65) (A)
and IL-6 (B) were detected on the same gel and share the same image of β tubulin, serving as loading Control.
FIGURE 5 | Evaluation of the effects of EMPA on isolated heart mitochondria. Direct effects of empagliflozin on mitochondria. (A) Calcium retention capacity of mouse
heart mitochondria (***p < 0.001 vs. all other study groups) and (B) representative Calcium tracing (n = 5).
cytokines and apoptosis-related proteins including IL-6 and
iNOS in the myocardium (Gordon et al., 2011). Although
we observed reduced levels of expression of both IL-6 and
iNOS in the myocardium, we did not find any changes in
phosphorylation and/or expression of NF-κB in the EMPA group
compared to the Control. Among targets that finely tune NF-
κB activity, it is proven that STAT3 acts as a suppressor of
NF-κB (Gordon et al., 2011). More specifically, STAT3 can
directly interact with NF-κB p65 subunit, leading to a dominant
inhibition of NF-κB activity and thus indirectly suppressing
cytokine induction of the iNOS promoter independently of
NF-κB phosphorylation or expression in vitro (Yu et al.,
2002). This might be the explanation of our aforementioned
findings.
It has been assumed that some of the direct effects of
EMPA acting independently of SGLT2 inhibition may be in
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FIGURE 6 | Empagliflozin rescues ECs and H9C2 cells from hypoxia/reoxygenation injury. (A,B) MTT assay was used to assess the effect of EMPA in
hypoxia/reoxygenation setting. The indicated concentrations were used to treat H9C2 cells (A) and ECs (B). Both H9C2 and ECs, either untreated or treated with
AGE (1 mg/mL), were subjected to hypoxia/reoxygenation. Data normalized to control are reported as mean ± SD and representative of four different experiments
performed in triplicate (n = 12) (For H9C2, ***p < 0.001 EMPA 500nM vs. control and EMPA 100nM; **p < 0.01 EMPA 500 nM + AGE vs. control + AGE and EMPA
(Continued)
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FIGURE 6 | 100 nM + AGE; for ECs, **p < 0.01 EMPA 500 nM vs. control and EMPA 100 nM; *p < 0.05 EMPA 500 nM + AGE vs. control + AGE. (C,D) Histogram
representation of the relative cellular ATP content. Data are obtained from H9C2 cells and ECs treated as indicated (for H9C2, *p < 0.05 EMPA 500 nM vs. control;
***p < 0.001 EMPA 500 nM + AGE vs. control + AGE and EMPA 100nM + AGE; for ECs, ***p < 0.001 EMPA 500 nM vs. control and EMPA 100 nM; **p < 0.01
control + AGE vs. EMPA 100nM + AGE, EMPA 500 nM + AGE vs. control + AGE, ***p < 0.001 EMPA 500nM + AGE vs. EMPA 100 nM + AGE). Data are reported
as mean ± SD and representative of four different experiments performed in triplicate (n = 12). (E) Cell extracts from H9C2 cells treated, with or without AGE (1
mg/mL), and with Empagliflozin at the indicated concentrations, were subjected to hypoxia/reoxygenation and analyzed for RAGE content, and normalized to β-actin
Data are representative of four different experiments performed in triplicate (n = 12).
part responsible for the established cardioprotective effects
of the drug. In this aspect a recent study showed that
EMPA has direct effects on cardiomyocytes through lowering
cytoplasmic sodium [Na+]c and calcium [Ca2+]c. These effects
are mainly mediated via Na+/H+ exchanger (NHE) activity,
independently of SGLT2 (Baartscheer et al., 2017). Therefore,
we investigated if EMPA has direct effect in H9C2 cells and
in ECs under hypoxia/reoxygenation. EMPA is a very potent
and selective SGLT2 inhibitor with an IC50 ∼3 nM and Cmax
from clinical dosing ∼500 nM; concentrations between 100
and 500 nM block effectively and selectively SGLT2 without
significant inhibition of SGLT1 (Panchapakesan et al., 2013).
Based on the above statements we use 100 and 500 nM
and interestingly, we observed that treatment with 500 nM
EMPA increased cell viability in comparison to the control
in absence or in presence of AGE, and increased ATP
content in both cell types. The increased ATP is probably
the result of improved mitochondrial function since it has
been demonstrated that SGLT2 inhibitors may shift whole-
body metabolism from glucose to fat oxidation (Vettor et al.,
2017), therefore improving oxidative phosphorylation and
mitochondrial respiration.
In a very recent study EMPA reduced pro-inflammatory
signaling through amelioration of increased interferon-γ
(IFN-γ) in an in vivo model of T2D (Steven et al., 2017).
From a mechanistic sight of view, EMPA reduced epigenetic
changes induced by T2D, as it downregulated the activating
epigenetic mark histone3 lysine4 trimethylation (H3K4me3) of
the promoters of IFN-γ and iNOS. Moreover, EMPA decreased
serum oxidative stress biomarkers namely 3-nitrotyrosine
and 4-hydroxynonenal and dose-dependently increased
aldehyde dehydrogenase (ALDH-2) activity (Steven et al.,
2017), a mitochondrial antioxidant enzyme responsible for the
detoxification of tissues from MDA (Wenzel et al., 2007). In
compliance with the above-mentioned findings we have shown
that EMPA reduced circulating MDA levels and improved
mitochondrial function as shown in cells by increased ATP
cellular content. Thus, we can speculate that these effects along
with the observed reduction of iNOS can be attributed to
epigenomic changes present in T2D. Moreover, macrophage
infiltration present in the context of AMI and T2D (Lee et al.,
2017; Steven et al., 2017) can contribute to the induction
of a proinflammatory phenotype and oxidative stress in the
myocardium, while SGLT2 inhibition is shown to diminish this
process. EMPA’s redox regulating effects seem to be pleiotropic
as it acts both by upregulating endogenous antioxidant
mechanisms and interfering with epigenomic changes associated
with T2D.
Conclusively, EMPA reduces myocardial infarct size in
animals fed with WD through STAT3 activation and regulation
of inflammatory responses in the myocardium. Moreover, the
decrease in iNOS expression and the concomitant decrease in
lipid peroxidation is of great importance. While diabetes is a
redox disease, the redox regulation by EMPA in parallel with
its glucose-lowering effects can be pivotal in managing diabetes
and limiting myocardial infarction. Therefore, the assessment
of EMPA effects on myocardial necrosis and the elucidation of
the molecular mechanisms responsible for its cardioprotection
are of paramount importance. It would allow predicting whether
EMPA has such beneficial effects also in diabetic patients without
prior cardiovascular disease, or in non-diabetic patients with
cardiovascular disease.
STUDY LIMITATIONS
We know that SGLT2 is highly specifically expressed in the
kidney and very minimally in the heart (Chen et al., 2017).
Therefore, additional studies are essential in order to investigate
how EMPA would exert its effects on cardiomyocytes. One of the
main limitations of the present study is the mechanistic insight of
the role of STAT3mediating cardioprotection. Additional studies
to elucidate the exact cardioprotective mechanism of EMPA by
the use of established inhibitors in vivo are necessary to answer
this question. However, our study is able to stimulate research in
investigating the cardioprotective mechanisms of this drug in the
setting of I/R injury.
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